Journal of Oncology / 2015 / Article / Tab 1

Review Article

Evolving Concepts: Immunity in Oncology from Targets to Treatments

Table 1

B-7 family of receptor ligands expressed by antigen presenting cells and various malignancies: CD cluster derivation; B7.1 known as CD80; B7.2 known as CD86; CD-28 and CD-152 present on T-naïve cells; ICOS inducible costimulatory ligand; (+) with and (−) without; CD152 also known as CTLA4 cytotoxic T lymphocytes antigen-4; PD-1 programmed death-1 also known as CD279; PD-L1 programmed death-ligand 1 known as B7-H1 or CD274; PD-L2 programmed death-ligand 2, known as CD273 or B7-DC B-7 dendritic cell; IFN-γ interferon gamma; IL-2 interleukin 2; Ref reference.

B-7 family moleculesCD-designationMajor ligands on immune cellsRole immunity activation versus immune suppressionMalignancies expressing B-7 moleculesRef

B7.1CD80CD28; CTLA4 (CD152)(+) 2nd signal activation (−) second signal anergyCD-80 on acute myeloid leukemia cells[37]

B7.2CD86CD28; CTLA4 (CD152)(+) 2nd signal activation (−) second signal anergyCD-86 on chronic lymphatic leukemia cells [46]

B7-H1 (PD-L1)CD274PD-1 (CD279)Ligating PD-1 on T-cells suppresses CD8+ responseNone[47]

B7-H2; B7-H3; B7-H6; ICOS CD275CD278Immune suppressionDendritic cells infiltrating malignancies; cancer cells: hematologic malignancies, breast, gastrointestinal, lung, melanoma, bladder, and genitourinary cancers[48]

PD-L2 B7-DCCD273PD-1 (CD279)Immune suppression reduces IL-2 and IFN-γ secretion, decreases proliferation and cytotoxicity, and induces apoptosis in activated T-cellsPrimary mediastinal (thymic) large B-cell lymphoma[49]

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.